Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells

Iron deficiency has been associated with kidney injury. Deferasirox is an oral iron chelator used to treat blood transfusion-related iron overload. Nephrotoxicity is the most serious and common adverse effect of deferasirox and may present as an acute or chronic kidney disease. However, scarce data...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Sanchez, Diego, Gallegos-Villalobos, Angel, Fontecha-Barriuso, Miguel, Carrasco, Susana, Sanchez-Niño, Maria Dolores, Lopez-Hernandez, Francisco J, Ruiz-Ortega, Marta, Egido, Jesus, Ortiz, Alberto, Sanz, Ana Belén
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282523/
https://www.ncbi.nlm.nih.gov/pubmed/28139717
http://dx.doi.org/10.1038/srep41510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282523/
https://www.ncbi.nlm.nih.gov/pubmed/28139717
http://dx.doi.org/10.1038/srep41510

Ejemplares similares